Targeting GRPR in urological cancers--from basic research to clinical application

Mansi, Rosalba; Fleischmann, Achim; Mäcke, Helmut R.; Reubi, Jean-Claude (2013). Targeting GRPR in urological cancers--from basic research to clinical application. Nature Reviews. Urology, 10(4), pp. 235-244. Nature Publishing Group 10.1038/nrurol.2013.42

Full text not available from this repository. (Request a copy)

Gastrin releasing peptide (GRP) is a regulatory peptide that acts through its receptor (GRPR) to regulate physiological functions in various organs. GRPR is overexpressed in neoplastic cells of most prostate cancers and some renal cell cancers and in the tumoral vessels of urinary tract cancers. Thus, targeting these tumours with specifically designed GRP analogues has potential clinical application. Potent and specific radioactive, cytotoxic or nonradioactive GRP analogues have been designed and tested in various animal tumour models with the aim of receptor targeting for tumour diagnosis or therapy. All three categories of compound were found suitable for tumour targeting in animal models. The cytotoxic and nonradioactive GRP analogues have not yet shown convincing tumour-reducing effects in human trials; however, the first clinical studies of radioactive GRP analogues--both agonists and antagonists--suggest promising opportunities for both diagnostic tumour imaging and radiotherapy of prostate and other GRPR-expressing cancers.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Fleischmann, Achim and Reubi-Kattenbusch, Jean-Claude


500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health




Nature Publishing Group




Andrea Arnold

Date Deposited:

03 Apr 2014 14:54

Last Modified:

10 Oct 2019 15:09

Publisher DOI:


PubMed ID:



Actions (login required)

Edit item Edit item
Provide Feedback